Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Pharmacokinetics, Safety and Tolerability of Single Dose BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Subjects (An Open Label, Matched Pair, Two Center Study)

To investigate the pharmacokinetics of a single dose of BIIL 284 BS in patients with hepatic impairment in comparison to healthy subjects

Study Overview

• Status: Completed
• Conditions: Hepatic Insufficiency
• Intervention / Treatment: Drug: BIIL 284 BS

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 24 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Healthy Subjects

• Written informed consent signed and dated prior to participation into the study (including medication washout)
• Male of female 24-70 years of age
• All subjects should be within (+- 20 %) of their ideal body weight (Broca-Index)
• Healthy subjects must be able to be comparably matched to a hepatic impaired patient according to age (+- 5 years), weight (+- 30 lbs), gender, and smoking status
• Volunteers will have no evidence of clinically relevant concomitant disease based upon the following: a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, complete blood count (CBC) with differential and platelets, prothrombin time (PT), blood chemistry, hematology and urinalysis
• Female subjects need to be of non-childbearing potential (post-menopausal), tubal ligation or total hysterectomy) and had to provide a negative pregnancy test at the screening visit or subjects is a male
• Tested negative at the screening visit for the following drug screen panel (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids)

Patients with hepatic impairment

• Written informed consent signed and dated prior to participation into the study (including medication washout)
• Male of female 24-70 years of age
• All subjects should be within (+- 20 %) of their ideal body weight (Broca-Index)
• Proven history of cirrhosis confirmed by liver/spleen scan or biopsy (within one year)
• Hepatic impairment: A Child-Pugh classification of Class A, or B
• Volunteers will have no evidence of clinically relevant concomitant disease (other than hepatic impairment) based upon the following: a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, CBC with differential and platelets, prothrombin time (PT), blood chemistry, hematology and urinalysis
• Tested negative at the screening visit for the following drug screen panel (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids). Unless known drugs were being used for medicinal reasons. For this reason the sponsor and investigator were notified
• Female patients were of non-childbearing potential (post-menopausal), tubal ligation or total hysterectomy) and had to provide a negative pregnancy test at the screening visit

Exclusion Criteria:

Healthy subjects

• Tested positive for Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody
• Have a significant acute or chronic disease, which could have interfered with the objectives of the study
• Small or difficult to locate arm or hand veins that would impair the clinician's ability to draw multiple blood samples or to place a venous catheter
• Likely to need concomitant medication during the study period, which could interfere with the objectives of the study
• Had given a blood donation during the month preceding the study drug administration
• Alcohol consumption > 2 drinks daily (one drink defined as: 12 ounces of beer, 4 ounces of wine or 1.5 ounces of spirits)
• Coffee or tea consumption > 3 cups per day or xanthine containing drinks > 0.5 liter/day
• History of any clinically significant hematological, respiratory, cardiovascular, renal or central nervous system (CNS) disease or other medical condition that is capable of altering the metabolism or elimination of drugs, or of constituting a risk factor when taking the study drug
• History of drug addiction or alcoholism
• Any medical or psychological condition which could relapse during or immediately after the study
• Use of any drug or nutrient which could induce or inhibit hepatic microsomal enzymes within one month of the start of the study or longer based on the elimination half-life of the drug
• Use of experimental new drug one month prior to study drug administration
• Consumed any medicine whatsoever (including over the counter (OTC) drugs) within two weeks of the scheduled administration of the study drug

Patients with Hepatic Impairment

• Positive serology for HIV
• Have a significant acute or chronic disease (except hepatic disease), which is unstable or could interfere with the objectives of the study
• Small or difficult to locate arm or hand veins that would impair the clinician's ability to draw multiple blood samples or to place a venous catheter
• Have hepatocellular carcinoma, extrahepatic biliary obstruction, surgical portal-systemic shunting, acute hepatitis of any origin
• Digestive bleeding within one month of inclusion
• Likely to need concomitant medication during the study period, which could interfere with the objectives of the study
• Had given a blood donation during the month preceding study entry
• Coffee or tea consumption > 3 cups per day or xanthine containing drinks > 0.5 liter/day
• History of any clinically significant hematological, respiratory, cardiovascular, renal or CNS disease or other medical condition (except hepatic impairment) that is capable of altering the metabolism or elimination of drugs, or of constituting a risk factor when taking the study drug
• Any medical or psychological condition which could relapse during or immediately after the study
• Use of any drug or nutrient which could induce or inhibit hepatic microsomal enzymes within one month of the start of the study or longer based on the elimination half-life of the drug
• Use of experimental new drug within the previous month

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BIIL 284 BS, normal hepatic function	Drug: BIIL 284 BS
Experimental: BIIL 284 BS, mild hepatic impairment	Drug: BIIL 284 BS
Experimental: BIIL 284 BS, moderate hepatic impairment	Drug: BIIL 284 BS

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Plasma concentration-time profiles of the analytes at different time points	Up to 84 hours after drug administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum measured concentration of BIIL 315 ZW in plasma (Cmax)		Up to 84 hours after drug administration
Time from dosing to the maximum concentration of BIIL 315 ZW in plasma (tmax)		Up to 84 hours after drug administration
Area under the concentration-time curve of BIIL 315 ZW in plasma at different time points (AUC)		Up to 84 hours after drug administration
Terminal half-life of BIIL 315 ZW in plasma (t1/2)		Up to 84 hours after drug administration
Total mean residence time of BIIL 315 ZW in the body (MRTtot)		Up to 84 hours after drug administration
Total apparent clearance of BIIL 315 ZW in plasma after oral administration (CLtot/F)		Up to 84 hours after drug administration
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)		Up to 84 hours after drug administration
Number of patients with clinically relevant findings in vital signs	blood pressure, pulse rate	Up to 4 days after drug administration
Changes from baseline in spirometry		Pre-dose and 1 hour after drug administration
Number of patients with clinically relevant findings in laboratory tests		Up to 4 days after drug administration
Number of patients with clinically relevant findings in 12-lead ECG		Up to 4 days after drug administration
Changes from baseline in physical examination		Pre-dose and 4 days after drug administration
Number of patients with adverse events		Up to 11 days after drug administration

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start: March 1, 2000
• Primary Completion (Actual): September 1, 2000

Study Registration Dates

• First Submitted: October 15, 2014
• First Submitted That Met QC Criteria: October 15, 2014
• First Posted (Estimate): October 16, 2014

Study Record Updates

• Last Update Posted (Estimate): October 16, 2014
• Last Update Submitted That Met QC Criteria: October 15, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Liver Failure; Hepatic Insufficiency
• Other Study ID Numbers: 543.26